Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Eradication
Objectives Tegoprazan, a novel potassium-competitive acid blocker with rapid and effective antisecretory activity, was approved for the treatment of Helicobacter pylori infections in Korea in March 2020. However, real-world data regarding tegoprazan-based therapies are scarce. We compared the effica...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Korean College of Helicobacter and Upper Gastrointestinal Research
2024-06-01
|
| coleção: | The Korean Journal of Helicobacter and Upper Gastrointestinal Research |
| Assuntos: | |
| Acesso em linha: | http://helicojournal.org/upload/pdf/kjhugr-2024-0012.pdf |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|